Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

Synergy of purine-scaffold TLR7 agonist with doxorubicin on systemic inhibition of lymphoma in mouse model.

Gao D, Li W, Wang W, Cai Y, Wang Y, Luo X, Wei CC.

J Cancer. 2017 Sep 15;8(16):3183-3189. doi: 10.7150/jca.20015. eCollection 2017.

2.
3.

Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era.

Tao L, Clarke CA, Rosenberg AS, Advani RH, Jonas BA, Flowers CR, Keegan THM.

Br J Haematol. 2017 Jul;178(1):72-80. doi: 10.1111/bjh.14638. Epub 2017 May 25.

4.

Kinetics of Rituximab Excretion into Urine and Peritoneal Fluid in Two Patients with Nephrotic Syndrome.

Stahl K, Duong M, Schwarz A, Wagner AD, Haller H, Schiffer M, Jacobs R.

Case Rep Nephrol. 2017;2017:1372859. doi: 10.1155/2017/1372859. Epub 2017 Jan 24.

5.

Population pharmacokinetics of rituximab in patients with diffuse large B-cell lymphoma and association with clinical outcome.

Rozman S, Grabnar I, Novaković S, Mrhar A, Jezeršek Novaković B.

Br J Clin Pharmacol. 2017 Aug;83(8):1782-1790. doi: 10.1111/bcp.13271. Epub 2017 Mar 31.

6.

Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity.

Schmohl JU, Felices M, Oh F, Lenvik AJ, Lebeau AM, Panyam J, Miller JS, Vallera DA.

Cancer Res Treat. 2017 Oct;49(4):1140-1152. doi: 10.4143/crt.2016.491. Epub 2017 Feb 20.

7.

Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies.

England CG, Rui L, Cai W.

Eur J Nucl Med Mol Imaging. 2017 Mar;44(3):517-532. doi: 10.1007/s00259-016-3560-9. Epub 2016 Nov 14. Review.

PMID:
27844106
8.

Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.

Xu-Monette ZY, Li L, Byrd JC, Jabbar KJ, Manyam GC, Maria de Winde C, van den Brand M, Tzankov A, Visco C, Wang J, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Huh J, Ponzoni M, Ferreri AJ, Møller MB, Parsons BM, Winter JN, Wang M, Hagemeister FB, Piris MA, Han van Krieken J, Medeiros LJ, Li Y, van Spriel AB, Young KH.

Blood. 2016 Dec 29;128(26):3083-3100. doi: 10.1182/blood-2016-05-715094. Epub 2016 Oct 19.

9.

Low natural killer (NK) cell counts in peripheral blood adversely affect clinical outcome of patients with follicular lymphoma.

He L, Zhu HY, Qin SC, Li Y, Miao Y, Liang JH, Xia Y, Wang Y, Wu YJ, Wang L, Fan L, Li JY, Xu W.

Blood Cancer J. 2016 Aug 12;6(8):e457. doi: 10.1038/bcj.2016.67. No abstract available.

10.

The impact of FcγRIIa and FcγRIIIa gene polymorphisms on responses to RCHOP chemotherapy in diffuse large B-cell lymphoma patients.

Rožman S, Novaković S, Grabnar I, Cerkovnik P, Novaković BJ.

Oncol Lett. 2016 May;11(5):3332-3336. Epub 2016 Apr 1.

11.

CD19xCD3 DART protein mediates human B-cell depletion in vivo in humanized BLT mice.

Tsai P, Thayer WO, Liu L, Silvestri G, Nordstrom JL, Garcia JV.

Mol Ther Oncolytics. 2016 Mar 2;3:15024. doi: 10.1038/mto.2015.24. eCollection 2016.

12.

Isolation of recombinant antibodies directed against surface proteins of Clostridium difficile.

Shirvan AN, Aitken R.

Braz J Microbiol. 2016 Apr-Jun;47(2):394-402. doi: 10.1016/j.bjm.2016.01.017. Epub 2016 Mar 2.

13.

Immunotherapy in Chronic Lymphocytic Leukaemia (CLL).

Freeman CL, Gribben JG.

Curr Hematol Malig Rep. 2016 Feb;11(1):29-36. doi: 10.1007/s11899-015-0295-9. Review.

14.

Efficacy and safety of rituximab combined with chemotherapy in the treatment of diffuse large B-cell lymphoma: a meta-analysis.

Meng F, Zhong D, Zhang L, Shao Y, Ma Q.

Int J Clin Exp Med. 2015 Oct 15;8(10):17515-22. eCollection 2015.

15.

Inhibitory effect of Embelin on human acute T cell lymphoma Jurkat cells through activation of the apoptotic pathway.

Zhu XL, Jiang L, Qu F, Wang ZY, Zhao LM.

Oncol Lett. 2015 Aug;10(2):921-926. Epub 2015 Jun 11.

16.

Critical appraisal of rituximab in the maintenance treatment of advanced follicular lymphoma.

Aguiar-Bujanda D, Blanco-Sánchez MJ, Hernández-Sosa M, Galván-Ruíz S, Hernández-Sarmiento S.

Cancer Manag Res. 2015 Oct 27;7:319-30. doi: 10.2147/CMAR.S69145. eCollection 2015. Review.

17.

Therapeutic antibodies: their mechanisms of action and the pathological findings they induce in toxicity studies.

Suzuki M, Kato C, Kato A.

J Toxicol Pathol. 2015 Jul;28(3):133-9. doi: 10.1293/tox.2015-0031. Epub 2015 Jun 15. Review. Erratum in: J Toxicol Pathol. 2016 Jan;29(1):74.

18.

Lymphoma Immunotherapy: Current Status.

Zappasodi R, de Braud F, Di Nicola M.

Front Immunol. 2015 Sep 1;6:448. doi: 10.3389/fimmu.2015.00448. eCollection 2015. Review.

19.

Diagnostic Potential of Recombinant scFv Antibodies Generated Against Hemagglutinin Protein of Influenza A Virus.

Rajput R, Sharma G, Rawat V, Gautam A, Kumar B, Pattnaik B, Pradhan HK, Khanna M.

Front Immunol. 2015 Sep 2;6:440. doi: 10.3389/fimmu.2015.00440. eCollection 2015.

20.

Novel synthesizing method of pH-dependent doxorubicin-loaded anti-CD22-labelled drug delivery nanosystem.

Sun M, Wang J, Lu Q, Xia G, Zhang Y, Song L, Fang Y.

Drug Des Devel Ther. 2015 Sep 7;9:5123-33. doi: 10.2147/DDDT.S86764. eCollection 2015.

Supplemental Content

Support Center